Does Regeneron’s gene therapy milestone and buyback shift the bull case for Regeneron Pharmaceuticals (regn)? Simply Wall St 7d
Regeneron Pharmaceuticals analysts cut their forecasts following Q1 earnings Benzinga 17:47 Thu, 30 Apr Article paywall
Regeneron’s Pipeline In Focus As Fianlimab Melanoma Data Awaited Scrip Pharma Intelligence 18:31 Wed, 29 Apr
Regeneron's quarterly sales of Eylea drop below $1B for the first time in 8 years FiercePharma 17:15 Wed, 29 Apr